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permeability to proteins leads to the loss of protein-rich
ﬂuid from the intravascular to the interstitial space.
Although sepsis is the disease most commonly associated
with this phenomenon, many other diseases can lead to a
“sepsis-like” syndrome with manifestations of diffuse
pitting edema, exudative serous cavity effusions,
noncardiogenic pulmonary edema, hypotension, and, in
some cases, hypovolemic shock with multiple-organ failure.
The term capillary leak syndrome has been used to describe
this constellation of disease manifestations associated with
an increased capillary permeability to proteins. Diseases
other than sepsis that can result in capillary leak syndrome
include the idiopathic systemic capillary leak syndrome or
Clarkson’s disease, engraftment syndrome, differentiation
syndrome, the ovarian hyperstimulation syndrome,
hemophagocytic lymphohistiocytosis, viral hemorrhagic
fevers, autoimmune diseases, snakebite envenomation,
and ricin poisoning. Drugs including some interleukins,
some monoclonal antibodies, and gemcitabine can also
cause capillary leak syndrome. Acute kidney injury is
commonly seen in all of these diseases. In addition to
hypotension, cytokines are likely to be important in the
pathophysiology of acute kidney injury in capillary leak
syndrome. Fluid management is a critical part of the
treatment of capillary leak syndrome; hypovolemia and
hypotension can cause organ injury, whereas capillary
leakage of administered ﬂuid can worsen organ edema
leading to progressive organ injury. The purpose of this
article is to discuss the diseases other than sepsis that
produce capillary leak and review their collective
pathophysiology and treatment.
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Kidney International (2017) -, -–-I n various human diseases, an increase in capillarypermeability to proteins leads to the loss of protein-richﬂuid from the intravascular to the interstitial space.
Although sepsis is the disease most commonly associated
with this phenomenon, many other diseases can lead to a
“sepsis-like” syndrome with manifestations of diffuse pitting
edema, exudative serous cavity effusions, noncardiogenic
pulmonary edema, hypotension, and, in some cases, hypovo-
lemic shock with multiple-organ failure. The term capillary
leak syndrome has been used to describe this constellation
of disease manifestations associated with an increased capil-
lary permeability to proteins. Diseases other than sepsis that
can result in capillary leak syndrome include the idiopathic
systemic capillary leak syndrome (SCLS) or Clarkson’s dis-
ease, engraftment syndrome, differentiation syndrome,
ovarian hyperstimulation syndrome (OHSS), hemophago-
cytic lymphohistiocytosis (HLH), viral hemorrhagic fevers
(VHFs), autoimmune diseases, snakebite envenomation, and
ricin poisoning. Drugs, including some interleukins (ILs),
certain monoclonal antibodies, and gemcitabine can also
cause capillary leak syndrome. Acute kidney injury (AKI) is
commonly seen in all of these diseases. In addition to hypo-
tension, cytokines are likely to be important in the patho-
physiology of AKI in capillary leak syndrome. Fluid
management is a critical part of the treatment of capillary
leak syndrome; hypovolemia and hypotension can cause
organ injury, whereas capillary leakage of administered ﬂuid
can worsen organ edema, leading to progressive organ injury.
The purpose of this article is to discuss the diseases other than
sepsis that produce capillary leak and review their collective
pathophysiology and treatment.
Epidemiology
The true incidence of capillary leak syndrome is unknown. It
is likely that many cases of capillary leak are unrecognized and
labeled as culture-negative sepsis or are attributed to an
alternate pathophysiology such as hypoalbuminemia. Many of
the diseases leading to capillary leak syndrome are uncom-
mon, and in only a variable proportion of those with a pre-
disposing condition will a clinically signiﬁcant capillary leak
develop. Over a 26-year period at the Mayo Clinic, only
25 cases of SCLS (or Clarkson’s disease) were documented.1
Drug-induced capillary leak syndrome has a variable inci-
dence depending on the speciﬁc drug studied. In a study
of interleukin (IL)-2 administration to cancer patients,
severe ﬂuid retention developed in 16 of 25 patients.2
Conversely, there are only a handful of case reports of1
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treatment for chronic lymphocytic leukemia, the risk of severe
capillary leak is universal when the lymphocyte count is
>50.0  109/l.3 Capillary leak due to engraftment syndrome
following hematopoietic stem cell transplantation has an
incidence of 7% to 55%, depending on the deﬁnition of
engraftment syndrome used.4 Capillary leak due to differen-
tiation syndrome following the treatment of acute promye-
locytic leukemia with retinoic acid or arsenic trioxide occurs
inw25% of cases.5 In the example of OHSS, severe capillary
leak is seen in only 2% of cases.6 The incidence of adult HLH
was estimated to be 1 in 800,000 in Japan.7 Because the signs
and symptoms of HLH overlap with those of many other
diseases, it is likely that HLH is underdiagnosed. The pro-
portion of individuals with HLH in whom capillary leak
develops is unknown. Viral hemorrhagic fever is relatively
uncommon, though most of these patients demonstrate
capillary leak. In summary, the incidence of capillary leak
syndrome varies from common to very rare, depending on
the disease or drug in question. Patients with severe capillary
leak syndrome are likely to cluster in the intensive care unit,
and thus, practitioners who frequently round in the intensive
care unit will encounter these patients.
Idiopathic SCLS (i.e., Clarkson’s disease)
SCLS is a rare disorder characterized by episodic increases in
vascular permeability resulting in acute losses of protein-rich
ﬂuid from the intravascular to the interstitial space.1,8,9 A
typical presentation begins with a prodrome of fatigue,
dizziness, and ﬂulike symptoms followed by the rapid-onset
of shock, systemic pitting edema, hemoconcentration, and
hypoalbuminemia. Other common disease manifestations
include AKI, pleural and pericardial effusions, rhabdomyol-
ysis, and sometimes compartment syndrome of the extrem-
ities.1 After a variable number of days, the vascular
permeability spontaneously improves, and the blood pressure
stabilizes. During this recovery phase, life-threatening pul-
monary edema can develop.1,10–12 The frequency of episodes
can vary widely between patients, with intervals ranging from
days to years.13 The majority of patients have a detectable
monoclonal protein in the serum, although the importance of
the monoclonal protein in the disease pathogenesis is
unclear.1,14,15 SCLS is a diagnosis of exclusion and is often
confused with sepsis, angioedema, or anaphylactic shock.16
The elevation of multiple cytokines has been discovered in
the acute serum of patients with SCLS, although only
CXCL10 (C-X-C motif chemokine ligand 10) was shown to
be elevated in both the quiescent and acute sera compared
with controls.16 In another study, angiopoietin-2 and vascular
endothelial growth factor were increased in acute SCLS sera
compared with control sera.17 The ﬁnding that acute serum
from SCLS patients induces hyperpermeability in human
microvascular endothelial cells suggests that a soluble factor is
important in the capillary leak pathophysiology.17 The
appropriate disease-speciﬁc treatment of SCLS is currently
unknown. Successful abortive therapy with i.v. Ig has been2described in 6 patients,18–21 whereas theophylline treatment
to maintain high trough levels was successful in aborting at-
tacks in 2 patients.22 Successful abortive therapy with the
tumor necrosis factor-a (TNF-a) antagonist inﬂiximab was
described in a single case report.22 Prophylactic treatment
with i.v. Ig prevented further attacks in 15 of 18 patients in 1
series23 and successfully prevented recurrent attacks in mul-
tiple case series.18–21,24–29 Combined treatment with terbu-
taline and aminophylline or theophylline decreased the
frequency and severity of attacks in 2 small series,11,22
although another series questioned the beneﬁts of this
combination therapy.14
Drug-induced capillary leak syndrome
Several drugs have been shown to cause capillary leak syn-
drome. The cytokine IL-2 administered for the treatment of
malignancy has been shown to cause edema, dyspnea, fever,
chills, nausea, vomiting, and diarrhea.2 In an animal model,
IL-2 caused an increase in the vascular permeability to
albumin.30 The cytokines IL-11 and IL-12 have also been
associated with capillary leak syndrome.31,32 The use of
gemcitabine for malignant diseases has resulted in systemic
edema, hypotension, noncardiogenic pulmonary edema, and
AKI.33–36 Studies of gemcitabine in lung cancer patients
demonstrated signiﬁcant increases in IL-2 and TNF-a in
response to therapy.37
Monoclonal antibodies can acutely activate large numbers
immune cells leading to abrupt increases in several cyto-
kines.38 This form of capillary leak syndrome, or cytokine
release syndrome, is characterized by the onset of symptoms
minutes to hours after the monoclonal antibody has been
administered. OKT3 is a monoclonal antibody that inhibits
CD3 on T cells. OKT3 administration causes fever, chills,
dyspnea, wheezing, hypotension, tachycardia, nausea, and
vomiting.39 The ﬁrst dose reaction to OKT3 is associated with
increases in TNF-a, IL-2, and interferon-g.40 More severe
reactions have been correlated with greater increases in serum
TNF-a.39 The treatment of hematologic malignancies with
the monoclonal antibodies rituximab and alemtuzumab has
resulted in the cytokine release syndrome.38 Rituximab has
been shown to increase TNF-a and IL-6 associated with
capillary leak syndrome in B-cell leukemia patients,3 whereas
alemtuzumab has been shown to increase TNF-a, interferon-g,
and IL-6.41 Perhaps the best example of acute drug-induced
capillary leak with multiple-organ injury comes from
the study of the anti–CD-28 monoclonal antibody
TGN1412.42 Within hours of the administration of TGN1412
to 6 healthy volunteers, hypotension, bilateral pulmonary
inﬁltrates, disseminated intravascular coagulation, and acute
kidney injury with metabolic acidosis requiring continuous
renal replacement therapy developed in all patients. There
were large increases of multiple cytokines in all patients. In
the 2 most critically ill patients, IL-6 and IL-4 were increased
out of proportion to other patients. Steroids have been shown
to be effective in ameliorating the signs and symptoms of
drug-induced capillary leak syndrome.30,33–35,38,42Kidney International (2017) -, -–-
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Engraftment syndrome occurs after hematopoietic stem cell
transplantation, usually within 4 days of granulocyte recovery,
and is mediated by the release of inﬂammatory cytokines such
as IL-1, TNF-a, and interferon-g.4 Clinical manifestations
include fever, hypotension, edema, ascites, pleural effusions,
noncardiogenic pulmonary edema, and variable renal
dysfunction.4 The incidence of engraftment syndrome varies
with the type of transplant (e.g., autologous, allogeneic,
syngeneic) and has widely discrepant estimations and
outcome data due to differing deﬁnitions and overlap with
other similar syndromes. AKI is common, with an incidence
of 26% in 1 study of autologous stem cell transplantation
patients.43 Capillary leak due to engraftment syndrome
responds to treatment with steroids.44
Differentiation (retinoic acid) syndrome
Differentiation syndrome is a complication occurring in
w25% of patients with acute promyelocytic leukemia who
undergo induction treatment with either all-trans retinoic
acid or arsenic trioxide. This complication usually occurs
10 to 12 days after initiating treatment and is characterized by
pulmonary inﬁltrates, fever, pulmonary edema, pleural effu-
sions, systemic edema, hypotension, and AKI.5 AKI can be
seen in 28% of cases.5 The pathophysiology of differentiation
syndrome involves chemokine release from differentiated
acute promyelocytic leukemia cells and the upregulation of
integrins and adhesion molecules on differentiated acute
promyelocytic leukemia cells as well as target tissues. These
events facilitate the inﬁltration of leukemic cells into target
organs, particularly the lungs.5 Steroids are effective in the
treatment of capillary leak caused by the differentiation
syndrome.5,45
Ovarian hyperstimulation syndrome
OHSS is a rare complication that occurs as a result of the
induction of ovulation with ovary-stimulating agents.46 OHSS
is characterized by abdominal pain and ovarian enlargement
in mild cases and in capillary leak with subsequent edema
formation in the abdominal, pleural, and pericardial spaces in
severe cases.47 Although mild forms of ovarian hyperstimu-
lation syndrome are common, severe ovarian hyperstimula-
tion syndrome occurs in only 2% of patients.6 In 1 study of
209 patients with severe and critical OHSS, oliguria developed
in 29.7% and renal failure in 1.4%.48 The pathophysiology is
believed to stem from exogenous human chorionic gonado-
tropin administration, which causes the development of
multiple ovarian follicles that release large amounts of
vascular endothelial growth factor.49 Vascular endothelial
growth factor concentrations are signiﬁcantly greater in the
abdominal cavity compared with serum, resulting in capillary
leak focused in the abdominal cavity.49 The development of a
large volume of ascites coupled with massive ovarian
enlargement causes respiratory distress, increased abdominal
pressure, and AKI. Two different time courses of OHSS have
been described: early OHSS occurs at 3 to 9 days after humanKidney International (2017) -, -–-chorionic gonadotropin administration, whereas late OHSS
has an onset at 12 to 17 days after human chorionic gonad-
otropin and is due to early pregnancy-induced human cho-
rionic gonadotropin production.50 Risk factors for OHSS
include young age, low body weight, previous OHSS, and the
presence of polycystic ovarian syndrome.47 The ovarian
hyperstimulation syndrome is generally self-limited and
requires only supportive care; paracentesis may be necessary
in selected cases.51
Hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis is a multisystem disor-
der caused by a hyperactive, unregulated immune response.52
The normal immune response to an infectious agent involves
the termination of infected antigen-presenting cells; this both
resolves the infection and facilitates the downregulation of the
immune response. Termination of infected antigen-presenting
cells occurs by cytotoxic T-lymphocytes and natural killer cells
through the release of cytotoxic granules containing perforin
and granzymes. Genetic forms of HLH are caused by defects in
the cytotoxic granules such that antigen-presenting cells cannot
be terminated and the immune response continues to in-
crease.52 The importance of infections in the pathophysiology
of HLH is underscored by ﬁndings in mouse models that show
a viral trigger is necessary to initiate HLH.52 Acquired forms of
HLH can occur secondary to infectious (particularly Epstein-
Barr virus), autoimmune, or malignant causes. The exact
mechanism of HLH in secondary causes is unknown, but im-
mune hyperactivity is a consequence. In both primary and
secondary forms of HLH, activation of large numbers of
lymphocytes and macrophages results in hypercytokinemia,
leading to the multisystem abnormalities in HLH.52 TNF-a,
IFN-g, and IL-18 are commonly increased in patients with
HLH. The diagnostic criteria for HLH include identiﬁcation of
a known genetic mutation or fulﬁllment of 5 of 8 criteria: fever;
splenomegaly; cytopenias of at least 2 of 3 lineages in the pe-
ripheral blood-hemoglobin<9 g/100 ml; platelets<100 X 103/
ml; neutrophils <1  103/ml; hypertriglyceridemia
(fasting $265 mg/100 ml); hypoﬁbrinogenemia (#150 mg/
100 ml); hemophagocytosis in the bone marrow, spleen, or
lymph nodes; low or absent natural killer cell activity;
ferritin$500 ng/ml or soluble CD25>2400 U/ml.53 A study of
intensive care unit patients with HLH compared with those
without HLH suggested that a ferritin level of 3951 ng/ml was
the optimal maximum level for diagnosis based on a receiver-
operator curve.54 Pulmonary involvement and renal involve-
ment are also commonmanifestations of HLH.55 Intensive care
unit admission is required in as many as 50% of patients55;
indications for intensive care unit admission include acute
respiratory failure, shock, alteredmental status, andAKI.56 AKI
has been found in 16% to 62% of patients with HLH.55,57 The
most common causes of AKI in HLH are prerenal and acute
tubular necrosis (ATN), although cases due to tumor lysis
syndrome, collapsing focal segmental glomerulosclerosis,
minimal change disease, and thrombotic microangiopathy
have been described.57,58 The initial treatment of HLH depends3
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Those with HLH secondary to a rheumatologic condition or
infection who are clinically stable can be treated with disease-
speciﬁc therapy with or without steroids.53 In cases related to
infection, antibiotics and i.v. Ig can be beneﬁcial. Rituximab
has been advocated for HLH secondary to Epstein-Barr virus
infection. The current standard of care forHLH in patients who
are unstable, have a malignant cause of HLH, or are deterio-
rating despite disease-speciﬁc therapy and steroids is a com-
bination of dexamethasone and etoposide; intrathecal
methotrexate can be added for those with central nervous
system involvement.53,59 OnceHLH secondary to amalignancy
is controlled with steroids and etoposide, disease-speciﬁc
chemotherapy can be initiated.53
Hemorrhagic fever
VHF is another cause of capillary leak and is associated with
shock, thrombocytopenia, coagulopathy, and hemor-
rhage.60,61 Studies of patients with epidemic hemorrhagic
fever, hantavirus, and dengue hemorrhagic fever demonstrate
similar clinical courses. It should be noted that hantavirus can
cause 2 distinct clinical syndromes depending on the strain of
infecting virus (which has a geographic variation); hemor-
rhagic fever with renal syndrome and hantavirus pulmonary
syndrome.61 Renal failure is a less common manifestation in
hantavirus pulmonary syndrome infections. During the hy-
potensive phase of VHF, there is a signiﬁcant decrease in
blood pressure accompanied by hemoconcentration and a
stable plasma protein concentration (reﬂective of capillary
leakage of plasma).61–63 Direct evidence of capillary leak is
derived from studies in patients with epidemic hemorrhagic
fever who demonstrate an increase in the albumin disap-
pearance rate from the plasma in the setting of an increasing
hematocrit.64 Although the hematocrit increases early in the
course of VHF due to capillary leak, it often becomes sub-
normal after ﬂuid resuscitation and the development of
hemorrhage. The incidence of AKI varies among the hem-
orrhagic fevers, being relatively uncommon in dengue hem-
orrhagic fever but common in hantavirus hemorrhagic fever
with renal syndrome.65–67 Proteinuria and hematuria can be
seen in patients with VHF in both the presence66 and absence
of glomerular abnormalities62,65,68; acute interstitial nephritis
has been seen with the Puumala hantavirus.69 Most patients
with AKI will spontaneously recover with supportive care,
although a minority may temporarily require renal replace-
ment.61,65,70 Capillary leak is also believed to be important in
the pathophysiology of Ebola and Marburg viruses, although
fewer data are available in these patients.71,72 Treatment is
supportive in VHF.
Miscellaneous
Snakebite envenomation commonly causes coagulopathy,
hemorrhage, hypovolemic shock, and AKI.73,74 In these
patients, AKI is due to a combination of shock and
pigment-induced tubular injury (hemoglobinuria or myo-
globinuria depending on the type of venom). In a series of4200 patients from South India with venomous snakebites,
capillary leak syndrome developed in 2 of 200, although the
deﬁnition of capillary leak was not provided.74 Treatment of
snakebite envenomation includes administration of the
appropriate snake antivenom. Ricin is a highly potent toxin
derived from castor beans that targets ribosomes and sub-
sequently inhibits protein synthesis causing cell death.75
Damage to endothelial cells leads to capillary leak, hemor-
rhage, and multiple organ failure.75 Use of the ricin A chain
conjugated to a monoclonal antibody as a chemothera-
peutic agent causes hypotension, edema, effusions, and
AKI.76,77 AKI is common regardless of the route of ricin
administration and is most commonly ATN due to shock,
although proteinuria and hematuria have been reported.75
Capillary leak syndrome has also rarely been reported in
autoimmune diseases including Kawasaki disease,78 anti-
phospholipid antibody syndrome,79 Sjögren syndrome,
systemic sclerosis, and polymyositis.80
Pathophysiology
All of the diseases causing capillary leak syndrome share the
same underlying pathophysiologic abnormality—an increase
in capillary permeability to proteins.8,9,18,30,64 As a result,
there is a loss of protein-rich ﬂuid from the intravascular to
the interstitial space. In all cases, hypercytokinemia is believed
to be the underlying cause of capillary leak. In a study of a
patient with SCLS, Atkinson et al.9 estimated that substances
in the plasma of at least 200 kDa, but not more than 900 kDa,
were leaked into the interstitial space. (For comparison,
albumin has a molecular weight of 66.5 kDa.) In their study,
Atkinson et al.9 measured a 30% to 50% loss of albumin from
the intravascular space during the ﬁrst 12 hours of the
capillary leak phase.
The ability of the endothelium to serve as a barrier between
the intravascular and interstitial spaces depends on the integrity
of binding between neighboring endothelial cells.81,82 Endo-
thelial cells bind to neighboring cells through 2 types of cell
junctions: adherens junctions (AJs) and tight junctions. In
addition to the brain, AJs appear to be the most important
component of endothelial cell-to-cell binding and thus
permeability.82 Vascular endothelial cadherin is a major
component of the AJ.81 Administration of blocking antibodies
to vascular endothelial cadherin in mice increases vascular
permeability in the heart and lungs.83 Mild inﬂammatory
stimuli cause vascular endothelial cadherin internalization,
whichweakens the AJ and increases permeability butmaintains
the integrity of the endothelial architecture.84 Greater inﬂam-
matory stimuli cause endothelial cell separation, resulting in
gaps between endothelial cells and in signiﬁcant increases in
permeability.84 Sepsis and individual cytokines have been
shown to increase vascular permeability via disruption of the
AJ.81,84,85 Incubation of human microvascular endothelial cells
with serum obtained from patients during an acute attack of
SCLS caused reduced vascular endothelial cadherin localization
at the AJ, decreased the integrity of the AJ, and increased
microvascular permeability.17 Incubation of humanKidney International (2017) -, -–-
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affect the AJ. The authors hypothesize that during the capillary
leak phase, a soluble factor in the plasma increases endothelial
permeability leading to capillary leak. Although alterations in
endothelial cell junctions have not been studied in other causes
of capillary leak syndrome, the common clinical phenotype
among the diseases suggests a similar molecular
pathophysiology.
Hemodynamic manifestations
Loss of protein-rich ﬂuid from the intravascular space leads to
intravascular volume depletion, resulting in secondary acti-
vation of the renin, angiotensin, and aldosterone system; the
sympathetic nervous system; and the release of vasopressin.6,9
The resulting sodium and water retention results in systemic
edema and exudative serous cavity effusions.6,51,86 (Figure 1).
When the capillary leak is abrupt in onset and severe, as in
SCLS, viral hemorrhagic fever, OHSS, and ricin poisoning,
signiﬁcant hemoconcentration can occur.1,8,9,63,65,87–90 This
hemoconcentration can serve as an indicator of capillary leakL
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Figure 1 | Clinical manifestations of capillary leak syndrome. (a) In t
movement of ﬂuid and proteins from the intravascular to the interstitial s
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prerenal acute kidney injury or acute tubular necrosis (ATN) in more sev
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Kidney International (2017) -, -–-severity. Diseases that are slower in onset or that have he-
matologic involvement do not demonstrate hemoconcentra-
tion. In the most severe cases, all causes of capillary leak
syndrome can result in hypovolemic shock (SCLS,8,9,14
HLH,56,91,92 differentiation syndrome,5 OHSS,6 hemorrhagic
fever,63,65 engraftment syndrome,44 ricin,75 drug-induced
capillary leak [OKT3,39 gemcitabine,34 IL-2,93 anti-CD28
Ab,42 rituximab3]).
Pulmonary manifestations
Pleural effusions, which are exudative in nature,86 have been
demonstrated in all causes of capillary leak syndrome. Non-
cardiogenic pulmonary edema is also seen in severe cases of
capillary leak syndrome. In the case of SCLS, as capillary
permeability normalizes, ﬂuid that had accumulated in the
interstitial space is mobilized back into the intravascular
space. In patients who receive large volumes of i.v. ﬂuids
during resuscitation, life-threatening pulmonary edema once
the blood pressure stabilizes can develop.1,10–12 Non-
cardiogenic pulmonary edema after i.v. ﬂuid resuscitation isVolume
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diseases, noncardiogenic pulmonary edema can occur early in
the course of the disease or after large volumes of ﬂuid have
been administered. Additional pulmonary manifestations
include pulmonary hemorrhage in HLH45,94 and differentia-
tion syndrome,45 as well as acute respiratory distress syn-
drome in SCLS, HLH, OHSS, engraftment syndrome, and
drug-induced capillary leak syndrome.12,42,44,94,95 Although
pleural effusions and noncardiogenic pulmonary edema can
be seen in OHSS,88,96 the most common respiratory abnor-
malities observed are dyspnea and mild hypoxia due to the
presence of large-volume ascites that restricts diaphragmatic
descent.96 This leads to an increase in the work of breathing,
as well as low lung volumes.
Renal manifestations
AKI is a common manifestation of capillary leak syndrome.
The most common causes of AKI are prerenal due to intra-
vascular volume depletion followed by ATN.1,8,9,42,45,57,73
Animal models in other diseases suggest that cytokines
contribute to renal tubular injury.97–100 As such, in addition
to hypotension, a role for cytokines in the development of
ATN in capillary leak syndrome seems likely. In some cases of
SCLS, the development of rhabdomyolysis with resultant
myoglobinuria contributes to ATN.1 Myoglobinuria, intra-
vascular hemolysis with hemoglobinuria, and, rarely, cortical
necrosis are additional causes of AKI in patients with snake-
bite envenomation.73,74 Glomerular lesions associated with
nephrotic syndrome develop in a minority of patients with
HLH,57 whereas in patients with VHF and ricin poisoning, an
active urine sediment early in the course of their disease can
transiently develop, suggesting mild glomerular injury
(superimposed on prerenal and acute tubular necrosis).61,62,65
In addition to intravascular volume depletion, abdominal
compartment syndrome due to tense ascites may occur in
OHSS and contribute to AKI.95,101
Other systems
Because edema develops throughout the body, it is likely that
most systems are affected by edema accumulation. However,
large data sets on other organ systems in capillary leak syn-
drome are not available. Rhabdomyolysis and compartment
syndrome due to muscle edema can develop in patients with
SCLS.1 Abdominal pain, nausea, and vomiting are common
in patients with capillary leak. The documentation of intes-
tinal edema in a case of SCLS11 and the observation that
abdominal pain can worsen with progressive ﬂuid resuscita-
tion in patients with hemorrhagic fever62 suggest that edema
of the gastrointestinal tract is a mediator of abdominal pain in
capillary leak syndrome.
Differential diagnosis
The manifestations of moderate to severe capillary leak syn-
drome are often indistinguishable from sepsis and septic
shock.14,42,45,65,92,102 As such, empirical antimicrobial therapy
is generally warranted in patients suspected of having6capillary leak syndrome. Anaphylactic shock is also a differ-
ential diagnosis of acute hemodynamic collapse and should be
considered in the differential diagnosis of SCLS.16 Finally,
hereditary angioedema, acquired angioedema (C1 inhibitor
deﬁciency), as well as Gleich syndrome (angioedema with
eosinophilia) can present with edema of the skin, upper
airway, and gastrointestinal tract and be confused with
capillary leak syndrome.13
Management
Fluid management is the most critical element in the treat-
ment of capillary leak syndrome (Figure 2). The hemody-
namic proﬁle of patients with capillary leak can vary from
stable blood pressure with intact perfusion and ﬂuid overload
to fulminant hypovolemic shock. In those with mild hypo-
tension, blood pressure often responds to i.v. ﬂuids in the
form of crystalloids. In patients with severe shock, blood
pressure may be only partially responsive or refractory to i.v.
ﬂuid.8,9,11,42,62 Given the small number of patients with
capillary leak syndrome in the literature, there is a lack of
sufﬁcient evidence to guide the choice of ﬂuid therapy. Case
studies have tried albumin or plasma infusions in those in
who fail to respond to crystalloids.8,62 Although albumin is
theoretically an attractive choice for volume expansion in
these patients, its efﬁcacy is expected to be attenuated due to
ongoing albumin loss from the vascular space. High molec-
ular weight starches such as pentastarch (molecular weight,
264 kDa) and hetastarch (molecular weight, 450 kDa) are
theoretically attractive resuscitative ﬂuids in those with
capillary leak given that their size may exceed that of the
endothelial defect. A report of 2 patients with SCLS showed
that 10% pentastarch was successful at increasing the central
venous pressure and systemic blood pressure.103 One of the 2
patients was hypotensive with a low central venous pressure
despite receiving 9 L of normal saline solution. She subse-
quently received pentastarch, which normalized her hemo-
dynamics. Another case report details a patient with a history
of SCLS and lower extremity compartment syndrome due to
massive ﬂuid resuscitation during a previous admission.
During a second episode, the administration of hydroxyethyl
starch reduced the crystalloid requirement and prevented
complications of ﬂuid overload.27 Notably, volume resusci-
tation with hydroxyethyl starch has been associated with
increased mortality and AKI in critically ill patients compared
with other resuscitative ﬂuids.104 Because a signiﬁcant num-
ber of patients with capillary leak die during the shock phase,
the potential beneﬁt of high molecular weight starches
probably outweighs the risk in those with refractory shock.
Vasopressors can be administered to those who remain hy-
potensive despite the perception of adequate volume resus-
citation, although they are expected to be less effective given
that intravascular volume depletion underlies the shock in
these patients.56,62,103 Patients with capillary leak syndrome
are at high risk of noncardiogenic pulmonary edema during
ﬂuid resuscitation. In some patients, pulmonary edema de-
velops after the blood pressure has stabilized due to the returnKidney International (2017) -, -–-
Severe capillary leak Recovery phase or
mild capillary leak
Early major clinical manifestations Clinical manifestations
Hypotension, shock
AKI
+/- pleural effusion,
pulmonary edema
Treatment
Volume resuscitation with crystalloids
utilizing a bolus approach to provide  
the minimum effective volume
Supportive
care
Disease-specific
therapy
No response
Vasopressors
Refactory shock
Hetastarch or pentastarch
Spontaneous
recovery
Stable blood pressure
Systemic edema
Pulmonary edema,
pleural effusions
Ascites
Treatment
Loop diuretics
Loop diuretics + 25% albumin
Renal replacement therapy
Inadequate
response
Inadequate
response
Consider albumin
ba
Figure 2 | Management of capillary leak syndrome. (a) In cases of severe capillary leak, there is marked disruption of endothelial cell-to-cell
binding resulting in massive losses of protein-rich ﬂuid into the interstitial space. Hypotension, shock, and acute kidney injury (AKI) often
dominate the initial clinical picture. In these patients, the priority is to increase the blood pressure in order to optimize organ perfusion. The
initial strategy is to administer boluses of crystalloids with a goal of providing the minimum effective volume that optimizes blood pressure.
A ﬂuid-restrictive strategy is advocated to limit interstitial ﬂuid volume expansion. The next step in the management of persistent hypotension
is the administration of vasopressors. A trial of 25% albumin i.v. is an additional option, although its efﬁcacy is limited in those with a severe
capillary leak. In those who remain with refractory shock in the setting of low ﬁlling pressures, high molecular weight starches such as
hetastarch and pentastarch may be effective in expanding the intravascular volume. Supportive care with invasive and noninvasive ventilation
as well as renal replacement may be necessary in severe cases. When available, disease-speciﬁc therapy should be initiated as soon as possible
to facilitate recovery. (b) In cases of mild capillary leak or during the recovery phase from severe capillary leak, the endothelial injury is less,
resulting in stable blood pressure. In this setting, ﬂuid overload symptoms predominate (e.g., pulmonary edema, pleural effusions, acute
respiratory distress syndrome, systemic edema, ascites). Volume removal with loop diuretics is the ﬁrst-line therapy in these patients. In those
with marginal blood pressure and ﬂuid overload, the combination of loop diuretics and 25% albumin i.v. may facilitate volume removal. Patients
with AKI refractory to diuretics will require renal replacement.
E Siddall et al.: Capillary leak syndrome rev i ewof interstitial ﬂuid to the intravascular space. For these
reasons, a ﬂuid-restrictive strategy is advocated during
volume resuscitation.1,8,9,11,12,62,63 This is best achieved by
administering a ﬂuid bolus, followed by reassessment of the
intravascular volume and pulmonary status before further i.v.
ﬂuid administration. Once the blood pressure has stabilized
for a period of time, diuretic therapy should be initiated to
prevent the development of pulmonary edema.10,11,62
In patients who present with a stable blood pressure and
show signs of ﬂuid overload, loop diuretics are the ﬁrst-line
therapy.34,35 In some patients with marginal blood pressure
and ﬂuid overload, but intact perfusion, the combination of
albumin and diuretics has been successful for removing vol-
ume.6 Patients in whom AKIwith oliguria develops are likely to
require renal replacement therapy. In those with hemodynamic
instability, continuous renal replacement is favored over inter-
mittent hemodialysis. In addition, continuous renal replace-
ment therapy may be preferable to intermittent hemodialysis in
those withmarked anasarca to allowmore rapid control of ﬂuid
overload. In the case of patients with OHSS who present with
hypovolemia and respiratory distress due to massive ascites,
paracentesis with colloid replacement has improved hemody-
namics and relieved respiratory distress.95,101Kidney International (2017) -, -–-In addition to ﬂuid therapy, steroid therapy has demon-
strated efﬁcacy in capillary leak syndrome due to drugs,
engraftment syndrome, differentiation syndrome, HLH, and
autoimmune diseases. Because capillary leak syndrome is
generally believed to be a cytokine-mediated disease, the
beneﬁt of steroids presumably relates to their ability to reduce
the expression of multiple cytokines.105 The reason that ste-
roids are ineffective in some cases of capillary leak syndrome
is unknown. It is possible that diseases causing capillary leak
syndrome unresponsive to steroids are due to endothelium-
damaging substances that are not affected by steroids.
In patients with SCLS, i.v. Ig is currently the most
promising therapy for both acute treatment and long-term
prevention. Although data are limited and no guidelines
exist, the available data suggest that i.v. Ig should be initiated
immediately in a patient suspected of having SCLS. Case
studies have used a dose of 1 g/kg per day for 2 days.18,21
Mounting data suggest that i.v. Ig is the treatment of choice
for the prevention of recurrent SCLS attacks and should be
offered to all patients. Doses of 2 g/kg monthly of i.v. Ig are
the most commonly used for prevention.23 Beyond the use of
i.v. Ig in patients with HLH who have active infections, there
are no available data on i.v. Ig in other forms of capillary leak.7
r ev i ew E Siddall et al.: Capillary leak syndromeSummary
A diverse set of diseases can give rise to capillary leak syn-
drome. The common pathophysiologic abnormality in each
disease is an increase in the vascular permeability to proteins
due to hypercytokinemia. Evidence derived from SCLS sug-
gests that disruption of the endothelial AJ may be the
mechanism by which cytokines increase vascular perme-
ability.17 This increase in vascular permeability results in the
loss of protein-rich ﬂuid from the intravascular to the inter-
stitial space and thus are signs and symptoms due to intra-
vascular volume depletion and interstitial volume expansion.
Loss of ﬂuid from the intravascular space results in hypo-
volemia and prerenal azotemia in mild cases, whereas
hypovolemic shock and AKI occur in severe cases. Accumu-
lation of ﬂuid in the interstitial space results in systemic
pitting edema and visceral effusions in mild cases, whereas
noncardiogenic pulmonary edema, acute respiratory distress
syndrome, rhabdomyolysis, and gut edema develop in severe
cases. AKI appears to be a consequence of hypovolemia and
hypotension in most cases, although cytokine-induced injury
may also be important. In select cases, intra-abdominal
hypertension, rhabdomyolysis, and glomerular disease may
also contribute to AKI. Fluid management is the most
important component of therapy in patients with capillary
leak. Judicious use of resuscitative crystalloid ﬂuids may sta-
bilize blood pressure and ameliorate AKI in mild cases of
capillary leak, although ﬂuids can lead to progressive inter-
stitial ﬂuid accumulation with subsequent organ injury. In
patients with shock refractory to crystalloids and vasopres-
sors, high molecular weight starches may have a role in vol-
ume resuscitation despite the risk of AKI. Given the
propensity for life-threatening pulmonary edema and acute
respiratory distress syndrome, diuretics should be instituted
once hemodynamic stability is achieved. When available,
disease-speciﬁc therapy to reduce cytokine production and
thus reverse the capillary leak is indicated. Steroids are
effective in several causes of capillary leak syndrome. An
effective abortive treatment in some patients with SCLS
appears to be i.v. Ig and seems to be the most effective agent
for preventing further attacks. It is important to consider
capillary leak syndrome in any patient who presents with
sepsis syndrome, in particular, when no clear infectious
process can be identiﬁed. Increased awareness of this problem
will lead to increased identiﬁcation of cases and eventually
better insight into the pathogenesis and treatment of capillary
leak syndrome.
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